SK13252003A3 - Použitie derivátov pyridoindolónu na prípravu protinádorových liečiv - Google Patents

Použitie derivátov pyridoindolónu na prípravu protinádorových liečiv Download PDF

Info

Publication number
SK13252003A3
SK13252003A3 SK1325-2003A SK13252003A SK13252003A3 SK 13252003 A3 SK13252003 A3 SK 13252003A3 SK 13252003 A SK13252003 A SK 13252003A SK 13252003 A3 SK13252003 A3 SK 13252003A3
Authority
SK
Slovakia
Prior art keywords
methyl
hydrogen
formula
compounds
ethyl
Prior art date
Application number
SK1325-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Bernard Bourrie
Pierre Casellas
Jean-Marie Derocq
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of SK13252003A3 publication Critical patent/SK13252003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1325-2003A 2001-04-27 2002-04-26 Použitie derivátov pyridoindolónu na prípravu protinádorových liečiv SK13252003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone
PCT/FR2002/001449 WO2002087574A2 (fr) 2001-04-27 2002-04-26 Utilisation de derives de pyridoindolone pour la preparation de medicaments anticancereux

Publications (1)

Publication Number Publication Date
SK13252003A3 true SK13252003A3 (sk) 2004-03-02

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
SK1324-2003A SK13242003A3 (sk) 2001-04-27 2002-04-26 Kombinácia s obsahom pyridoindolónového derivátu a protinádorového činidla, farmaceutická kompozícia, ktorá ju obsahuje, a jej použitie
SK1325-2003A SK13252003A3 (sk) 2001-04-27 2002-04-26 Použitie derivátov pyridoindolónu na prípravu protinádorových liečiv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK1324-2003A SK13242003A3 (sk) 2001-04-27 2002-04-26 Kombinácia s obsahom pyridoindolónového derivátu a protinádorového činidla, farmaceutická kompozícia, ktorá ju obsahuje, a jej použitie

Country Status (34)

Country Link
US (3) US7524857B2 (de)
EP (2) EP1385512B1 (de)
JP (2) JP2004531538A (de)
KR (1) KR100847413B1 (de)
CN (2) CN1240382C (de)
AR (1) AR034313A1 (de)
AT (2) ATE338548T1 (de)
BG (2) BG108260A (de)
BR (1) BR0209138A (de)
CA (2) CA2444334A1 (de)
CY (1) CY1105813T1 (de)
CZ (2) CZ295224B6 (de)
DE (2) DE60214533T2 (de)
DK (2) DK1385512T3 (de)
EA (1) EA005930B1 (de)
EE (2) EE200300465A (de)
ES (2) ES2271264T3 (de)
FR (1) FR2823975B1 (de)
HK (2) HK1059895A1 (de)
HU (2) HUP0400744A2 (de)
IL (4) IL158312A0 (de)
IS (1) IS2441B (de)
MX (1) MXPA03009639A (de)
NO (2) NO20034787L (de)
NZ (1) NZ528671A (de)
PL (2) PL366910A1 (de)
PT (2) PT1385512E (de)
RS (2) RS50791B (de)
RU (1) RU2292888C9 (de)
SK (2) SK13242003A3 (de)
TW (1) TWI252104B (de)
UA (1) UA74876C2 (de)
WO (2) WO2002087574A2 (de)
ZA (1) ZA200307785B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0755454B1 (de) * 1994-04-13 2008-02-13 The Rockefeller University Aav-vermittelte überbringung von dna in zellen des nervensystems
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
FR2765582B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CZ20032909A3 (en) 2004-06-16
WO2002087575A1 (fr) 2002-11-07
DE60214533D1 (de) 2006-10-19
RS50791B (sr) 2010-08-31
EP1385513B1 (de) 2006-09-06
DE60214533T2 (de) 2007-06-21
WO2002087574A3 (fr) 2003-02-13
CA2443012A1 (en) 2002-11-07
KR20040015138A (ko) 2004-02-18
NO20034787L (no) 2003-12-23
AR034313A1 (es) 2004-02-18
CZ299465B6 (cs) 2008-08-06
IL158266A0 (en) 2004-05-12
IS6984A (is) 2003-10-09
JP2004531538A (ja) 2004-10-14
FR2823975B1 (fr) 2003-05-30
EA005930B1 (ru) 2005-08-25
CZ20032910A3 (en) 2004-07-14
FR2823975A1 (fr) 2002-10-31
US6967203B2 (en) 2005-11-22
DE60208365T2 (de) 2006-09-07
UA74876C2 (en) 2006-02-15
IS2441B (is) 2008-11-15
IL158312A (en) 2009-09-01
DK1385513T3 (da) 2007-01-15
YU83903A (sh) 2006-08-17
CN1240382C (zh) 2006-02-08
US7524857B2 (en) 2009-04-28
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
NZ528671A (en) 2004-06-25
IL158312A0 (en) 2004-05-12
EP1385513A1 (de) 2004-02-04
EP1385512B1 (de) 2005-12-28
HUP0400744A2 (hu) 2004-06-28
CA2444334A1 (fr) 2002-11-07
PT1385513E (pt) 2007-01-31
IL158266A (en) 2009-09-01
YU83403A (sh) 2006-08-17
JP2004528343A (ja) 2004-09-16
RU2003130376A (ru) 2005-04-10
ES2254683T3 (es) 2006-06-16
RS50790B (sr) 2010-08-31
HK1059895A1 (en) 2004-07-23
US20050272760A1 (en) 2005-12-08
KR100847413B1 (ko) 2008-07-18
PL366916A1 (en) 2005-02-07
EA200301062A1 (ru) 2004-04-29
NO20034785D0 (no) 2003-10-24
DK1385512T3 (da) 2006-05-22
SK13242003A3 (sk) 2004-03-02
ZA200307785B (en) 2004-10-06
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
US20040122027A1 (en) 2004-06-24
HK1060066A1 (en) 2004-07-30
ATE314070T1 (de) 2006-01-15
CY1105813T1 (el) 2011-02-02
CN1505510A (zh) 2004-06-16
EP1385512A2 (de) 2004-02-04
DE60208365D1 (de) 2006-02-02
PT1385512E (pt) 2006-05-31
US20040122036A1 (en) 2004-06-24
BG108260A (bg) 2004-12-30
CN1505511A (zh) 2004-06-16
HUP0400745A2 (hu) 2004-08-30
CA2443012C (fr) 2009-07-28
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
CZ295224B6 (cs) 2005-06-15
US7160895B2 (en) 2007-01-09
PL366910A1 (en) 2005-02-07
ES2271264T3 (es) 2007-04-16
EE200300465A (et) 2003-12-15
EE200300466A (et) 2003-12-15
RU2292888C2 (ru) 2007-02-10
MXPA03009639A (es) 2004-06-30
NO20034787D0 (no) 2003-10-24
BR0209138A (pt) 2004-06-08

Similar Documents

Publication Publication Date Title
CN106536480B (zh) 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法
US20200071272A1 (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
US9616081B2 (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate
JP2002523506A (ja) 肥満の処置のためのピロロキノリン
US7160895B2 (en) Use of pyridoindolone derivatives for the preparation of medicinal products
KR20160078504A (ko) 단백질 키나제 저해제
RU2657604C2 (ru) Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана
JP2017501124A (ja) プロテインキナーゼ阻害剤

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure